Growing evidence from several medical disorders proves that placebo and nocebo responses play a significant role in, and can thus contribute to, the outcome of medical therapies. Parkinson's disease (PD) is among these disorders, a neurodegenerative disorder comprising cardinal motor symptoms associated with a deficit in dopamine production and electrophysiological disbalance in the basal ganglia, some of which (such as the subthalamic nucleus; STN) can be targeted for chronic electrical stimulation (deep brain stimulation) for symptom relief by modulation of diseased neuronal rhythms. Expectations regarding the effect of a treatment and associative learning/behavioural conditioning processes have been identified as main mechanisms underlying placebo responses (for review see, for example, Enck et al. 2013). In recent years it was shown that administration of placebo drugs, which PD patients expect to be potent antiparkinsonian (dopaminergic) medication, induces a substantial dopamine release in the striatum (de la Fuente-Fernandez et al. 2001). Using the possibility of intraoperative recordings in deep brain stimulation surgery, Fabrizio Benedetti's group furthermore showed that alterations in the firing rate of single neurons in the STN were associated with improvement in a motor symptom (rigidity) (Benedetti et al. 2004). However, these different facets of placebo responses induced through expectation were only evident for some patients, so called ‘placebo responders’. Benedetti's group is now targeting learning mechanisms in PD in order to convert ‘placebo non-responders’ to ‘responders’ – mechanisms already investigated in pain and other disorders. On a physiological level, Benedetti et al. now report in this issue of The Journal of Physiology how conditioning can turn thalamic neurons that do not respond to placebos (placebo ‘non-responder’ neurons) into a placebo ‘responder’ (Benedetti et al. 2016). As a result these neurons respond to a placebo the same way as they would to a medically effective treatment. Conditioning was achieved in PD patients with the dopaminergic drug apomorphine, given up to four days in a row before the surgical implantation of electrodes for deep brain stimulation. Intraoperatively, apomorphine was replaced with a placebo (saline infusions) and single neurons in the thalamus were recorded. If apomorphine was repeatedly administered before placebo administration, the placebo induced increased neuronal activity associated with improvement in the motor symptom of rigidity. The authors found that magnitude of neuronal changes and clinical effect were correlated with the number of previous drug administrations. If a placebo was given after four previous administrations of apomorphine, the placebo response could be as strong as the drug response, and this effect lasted up to 24 h. These findings highlight some remarkable aspects in placebo research: (1) it is possible to maximize a placebo response by conditioned learning in PD, (2) it is possible to identify a neuronal correlate of this mechanism by listening to single neurons, and (3) there may be an impact on future therapy and a widening of the therapeutic window in PD by reducing drug intake while obtaining the same clinical benefit. As a limitation of the current work it should be briefly mentioned that the clinical effect reported here was limited to rigidity – which is (in contrast to akinesia) one but not the core cardinal motor symptom in PD. Furthermore, recordings in this study were not performed in the STN, the typical target for deep brain stimulation to improve akinesia and rigidity, but were rather performed in the motor thalamus – the output station of the basal ganglia. In the future, recordings from the STN would be desirable. Moreover, taking the current understanding of deep brain stimulation as a neuromodulation technique in pathological cortical–subcortical oscillatory networks into account, one should supplement single- or multi-unit recording techniques with an oscillatory network approach. In the framework of deep brain stimulation, the combination of invasive local field potential recordings and non-invasive electroencephalography or magnetoencephalography offers a unique network approach in humans allowing the disentangling of brain activity patterns and brain function, especially regarding barely accessible deep-seated areas (Trenado et al. 2016). As the behavioural data and technical gadgets are available now, let's move beyond single neurons to listen to neuronal network oscillations responding to placebos.